PHILADELPHIA, Aug. 9, 2017 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today financial and operational results for the quarter ended June 30, 2017 and provided a corporate update.
Second Quarter Corporate Highlights
Initiating Phase 2 clinical trial in contactin-4 mutation-positive Attention Deficit Hyperactivity Disorder (“CNTN4+ ADHD”) (Part A) to confirm genetic responders to AEVI-001. Patient screening is anticipated to begin in the third quarter of 2017 and data is expected by mid-2018.
